{"id":981565,"date":"2026-07-14T21:03:06","date_gmt":"2026-07-15T01:03:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"},"modified":"2026-07-14T21:03:06","modified_gmt":"2026-07-15T01:03:06","slug":"tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","title":{"rendered":"Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SOUTH SAN FRANCISCO, Calif., July  14, 2026  (GLOBE NEWSWIRE) &#8212; Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.<\/p>\n<p>The stock options have an exercise price of\u00a0$0.8365\u00a0per share, which is equal to the closing price of Tenaya\u2019s common stock on\u00a0July 13, 2026.\u00a0Each stock option has a ten-year term and vests as follows over a total of four years: 1\/4<sup>th<\/sup>\u00a0of the original number of shares subject to the stock option shall vest on the one-year anniversary of the employee&#8217;s date of hire and 1\/48<sup>th<\/sup>\u00a0of the original number of shares subject to the stock option shall vest every month thereafter, subject to such employee\u2019s continued service with\u00a0Tenaya on each such date.<\/p>\n<p>The stock options are subject to the terms and conditions of the Tenaya Therapeutics Inc. 2024 Inducement Equity Incentive Plan and related forms of agreements and were granted as an inducement material to each new employee\u2019s acceptance of employment with Tenaya in accordance with NASDAQ Listing Rule 5635(c)(4).<\/p>\n<p>\n        <strong>About\u00a0Tenaya Therapeutics<\/strong><br \/>\n        <br \/>Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya\u2019s pipeline includes clinical-stage candidates TN-201, a gene therapy for\u00a0<em>MYBPC3<\/em>-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for\u00a0<em>PKP2<\/em>-associated arrhythmogenic right ventricular cardiomyopathy (ARVC);\u00a0and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD).\u00a0Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions.\u00a0 For more information, visit<strong>\u00a0<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J4Br29IkNhkCGnBTW-bZiNVNTaYyORpCdXKfSUubvF2wiE4NzPgLYa3CTynpEfe0ixWJ-nYa0OGK-qVNS-WloSPs3ztZvS5206LNTn6jJEYqdx17KtgCZx5_rtcpbTo45Se_EdNuNxi0rOeL9gTm9bppt10p3M-Rg4YxUGMpVltFSXr9T1YNqiKzsZQQOgLsXB4GY44RdXx1uPmw3D0EiBfudGJNt-JuICZV6mvjPJJKpJVfbz7MGahPc6GBqSWGNuN0A-_N4YNC8MzuRalR2c7n-WmKqOGPoqacDMRC0cM=\" rel=\"nofollow\" target=\"_blank\">www.tenayatherapeutics.com<\/a>.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjQ2MiM3NzA2OTk4IzIyMDk0NDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjJlOTg1MTctYmE2MC00ODE0LTk0YzctNzA1YmE4MTE1NmFlLTEyMjA5OTktMjAyNi0wNy0xNS1lbg==\/tiny\/Tenaya-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contact\r\nMichelle Corral\r\nVP, Corporate Communications and Investor Relations\r\nIR@tenayathera.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) &#8212; Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of\u00a0$0.8365\u00a0per share, which is equal to the closing price of Tenaya\u2019s common stock on\u00a0July 13, 2026.\u00a0Each stock option has a ten-year term and vests as follows over a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-981565","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) &#8212; Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of\u00a0$0.8365\u00a0per share, which is equal to the closing price of Tenaya\u2019s common stock on\u00a0July 13, 2026.\u00a0Each stock option has a ten-year term and vests as follows over a &hellip; Continue reading &quot;Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T01:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjQ2MiM3NzA2OTk4IzIyMDk0NDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-07-15T01:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\"},\"wordCount\":375,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjQ2MiM3NzA2OTk4IzIyMDk0NDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\",\"name\":\"Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjQ2MiM3NzA2OTk4IzIyMDk0NDY=\",\"datePublished\":\"2026-07-15T01:03:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjQ2MiM3NzA2OTk4IzIyMDk0NDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjQ2MiM3NzA2OTk4IzIyMDk0NDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","og_locale":"en_US","og_type":"article","og_title":"Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) &#8212; Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of\u00a0$0.8365\u00a0per share, which is equal to the closing price of Tenaya\u2019s common stock on\u00a0July 13, 2026.\u00a0Each stock option has a ten-year term and vests as follows over a &hellip; Continue reading \"Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-15T01:03:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjQ2MiM3NzA2OTk4IzIyMDk0NDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)","datePublished":"2026-07-15T01:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"},"wordCount":375,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjQ2MiM3NzA2OTk4IzIyMDk0NDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","name":"Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjQ2MiM3NzA2OTk4IzIyMDk0NDY=","datePublished":"2026-07-15T01:03:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjQ2MiM3NzA2OTk4IzIyMDk0NDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjQ2MiM3NzA2OTk4IzIyMDk0NDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=981565"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981565\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=981565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=981565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=981565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}